hydroxychloroquine has been researched along with Behavior Disorders in 8 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To perform a systematic review on the psychiatric adverse effects of chloroquine (CQ) and hydroxychloroquine (HCQ); to summarize what is known about psychiatric adverse effects of these drugs; to compare clinical trials, populational studies, and case report studies; and to increase awareness of the potential psychiatric adverse effects of these drugs." | 3.01 | Systematic Review of Psychiatric Adverse Effects Induced by Chloroquine and Hydroxychloroquine: Case Reports and Population Studies. ( Cao, B; Chakravarty, S; Greenshaw, AJ; Liu, YS; Passos, IC; Talarico, F, 2023) |
| "Among 873 subjects, 20% had a psychiatric diagnosis, most commonly depression." | 1.62 | Impact of Psychiatric Diagnosis and Treatment on Medication Adherence in Youth With Systemic Lupus Erythematosus. ( Chang, JC; Cidav, Z; Davis, AM; Klein-Gitelman, MS; Knight, AM; Mandell, DS, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (12.50) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 7 (87.50) | 2.80 |
| Authors | Studies |
|---|---|
| Talarico, F | 1 |
| Chakravarty, S | 1 |
| Liu, YS | 1 |
| Greenshaw, AJ | 1 |
| Passos, IC | 1 |
| Cao, B | 1 |
| Javelot, H | 1 |
| El-Hage, W | 1 |
| Meyer, G | 1 |
| Becker, G | 1 |
| Michel, B | 1 |
| Hingray, C | 1 |
| Yahya, AS | 1 |
| Khawaja, S | 1 |
| Chukwuma, J | 1 |
| Fujieda, Y | 1 |
| Nessaibia, I | 1 |
| Siciliano, D | 1 |
| Tahraoui, A | 1 |
| Chang, JC | 1 |
| Davis, AM | 1 |
| Klein-Gitelman, MS | 1 |
| Cidav, Z | 1 |
| Mandell, DS | 1 |
| Knight, AM | 1 |
| Garcia, P | 1 |
| Revet, A | 1 |
| Yrondi, A | 1 |
| Rousseau, V | 1 |
| Degboe, Y | 1 |
| Montastruc, F | 1 |
| Kremer, JM | 1 |
| Rynes, RI | 1 |
| Bartholomew, LE | 1 |
| Rodichok, LD | 1 |
| Pelton, EW | 1 |
| Block, EA | 1 |
| Tassinari, RB | 1 |
| Silver, RJ | 1 |
2 reviews available for hydroxychloroquine and Behavior Disorders
| Article | Year |
|---|---|
Systematic Review of Psychiatric Adverse Effects Induced by Chloroquine and Hydroxychloroquine: Case Reports and Population Studies.
Topics: Anxiety; Chloroquine; Drug-Related Side Effects and Adverse Reactions; Humans; Hydroxychloroquine; M | 2023 |
Diversity of neuropsychiatric manifestations in systemic lupus erythematosus.
Topics: Adrenal Cortex Hormones; Antibodies, Antinuclear; Autoantibodies; Cytokines; Humans; Hydroxychloroqu | 2020 |
6 other studies available for hydroxychloroquine and Behavior Disorders
| Article | Year |
|---|---|
COVID-19 and (hydroxy)chloroquine-azithromycin combination: Should we take the risk for our patients?
Topics: Azithromycin; Chloroquine; Coronavirus Infections; COVID-19; Drug Therapy, Combination; Humans; Hydr | 2020 |
The Use of "Novel Pharmacology" in the Treatment of COVID-19 and Potential Psychiatric Risks.
Topics: Adrenal Cortex Hormones; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Humans; Hyd | 2020 |
Why nobody discusses the adverse psychiatric effects of chloroquine in case it might become the future treatment against COVID-19?
Topics: Antiviral Agents; Chloroquine; COVID-19 Drug Treatment; Forecasting; Humans; Hydroxychloroquine; Men | 2020 |
Impact of Psychiatric Diagnosis and Treatment on Medication Adherence in Youth With Systemic Lupus Erythematosus.
Topics: Adolescent; Adolescent Behavior; Age Factors; Antirheumatic Agents; Child; Child Behavior; Comorbidi | 2021 |
Psychiatric Disorders and Hydroxychloroquine for Coronavirus Disease 2019 (COVID-19): A VigiBase Study.
Topics: Adenosine Monophosphate; Adult; Aged; Aged, 80 and over; Alanine; Antibodies, Monoclonal, Humanized; | 2020 |
Non-organic non-psychotic psychopathology (NONPP) in patients with systemic lupus erythematosus.
Topics: Adolescent; Adult; Aged; Antibodies, Antinuclear; Biopsy; Blood Sedimentation; Central Nervous Syste | 1981 |